KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Other Non-Current Liabilities for 2 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 56.04% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, down 56.04%, and an annual FY2025 reading of $2.1 million, down 56.04% over the prior year.
  • Other Non-Current Liabilities was $2.1 million for Q4 2025 at Recursion Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q1 2025 and bottomed at $1.0 million in Q3 2025.